BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shi K, Queiroz KC, Roelofs JJ, van Noesel CJ, Richel DJ, Spek CA. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model: PAR-2 reduces metastasis in pancreatic cancer model. J Pathol 2014;234:398-409. [DOI: 10.1002/path.4411] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Shi K, Spek CA. Authors' reply-Re: Shi et al. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. J Pathol 2014;234: 398-409. J Pathol 2015;236:130. [PMID: 25504568 DOI: 10.1002/path.4499] [Reference Citation Analysis]
2 Mußbach F, Ungefroren H, Günther B, Katenkamp K, Henklein P, Westermann M, Settmacher U, Lenk L, Sebens S, Müller JP, Böhmer FD, Kaufmann R. Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivo. Mol Cancer 2016;15:54. [PMID: 27473374 DOI: 10.1186/s12943-016-0538-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
3 Fink DM, Steele MM, Hollingsworth MA. The lymphatic system and pancreatic cancer. Cancer Lett 2016;381:217-36. [PMID: 26742462 DOI: 10.1016/j.canlet.2015.11.048] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
4 Zeeh F, Witte D, Gädeken T, Rauch BH, Grage-Griebenow E, Leinung N, Fromm SJ, Stölting S, Mihara K, Kaufmann R, Settmacher U, Lehnert H, Hollenberg MD, Ungefroren H. Proteinase-activated receptor 2 promotes TGF-β-dependent cell motility in pancreatic cancer cells by sustaining expression of the TGF-β type I receptor ALK5. Oncotarget 2016;7:41095-109. [PMID: 27248167 DOI: 10.18632/oncotarget.9600] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
5 Kanemaru A, Yamamoto K, Kawaguchi M, Fukushima T, Lin CY, Johnson MD, Camerer E, Kataoka H. Deregulated matriptase activity in oral squamous cell carcinoma promotes the infiltration of cancer-associated fibroblasts by paracrine activation of protease-activated receptor 2. Int J Cancer. 2017;140:130-141. [PMID: 27615543 DOI: 10.1002/ijc.30426] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
6 Ungefroren H, Witte D, Rauch BH, Settmacher U, Lehnert H, Gieseler F, Kaufmann R. Proteinase-Activated Receptor 2 May Drive Cancer Progression by Facilitating TGF-β Signaling. Int J Mol Sci 2017;18:E2494. [PMID: 29165389 DOI: 10.3390/ijms18112494] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ungefroren H, Gieseler F, Kaufmann R, Settmacher U, Lehnert H, Rauch BH. Signaling Crosstalk of TGF-β/ALK5 and PAR2/PAR1: A Complex Regulatory Network Controlling Fibrosis and Cancer. Int J Mol Sci 2018;19:E1568. [PMID: 29795022 DOI: 10.3390/ijms19061568] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
8 Cote B, Rao D, Alany RG, Kwon GS, Alani AWG. Lymphatic changes in cancer and drug delivery to the lymphatics in solid tumors. Adv Drug Deliv Rev 2019;144:16-34. [PMID: 31461662 DOI: 10.1016/j.addr.2019.08.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
9 Tieken C, Versteeg HH. Anticoagulants versus cancer. Thromb Res 2016;140 Suppl 1:S148-53. [PMID: 27067969 DOI: 10.1016/S0049-3848(16)30114-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
10 Qian X, Chen Z, Chen SS, Liu LM, Zhang AQ. Integrated Analyses Identify Immune-Related Signature Associated with Qingyihuaji Formula for Treatment of Pancreatic Ductal Adenocarcinoma Using Network Pharmacology and Weighted Gene Co-Expression Network. J Immunol Res 2020;2020:7503605. [PMID: 32537471 DOI: 10.1155/2020/7503605] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Wojtukiewicz MZ, Hempel D, Sierko E, Tucker SC, Honn KV. Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis. Cancer Metastasis Rev 2015;34:775-96. [PMID: 26573921 DOI: 10.1007/s10555-015-9599-4] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 11.3] [Reference Citation Analysis]
12 Duitman J, Hartl L, Roelofs JJTH, Bijlsma MF, Spek CA. Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation. Biomolecules 2021;11:1079. [PMID: 34439745 DOI: 10.3390/biom11081079] [Reference Citation Analysis]
13 Rohan Z, Olejar T, Matej R. Re: Shi et al. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. J Pathol 2014;234: 398-409. J Pathol 2015;236:128-9. [PMID: 25488199 DOI: 10.1002/path.4498] [Reference Citation Analysis]